Page contentsPage contents Key facts Decision Key facts Active substance acetylsalicylic acidrivaroxaban Therapeutic area Vascular disorders Decision number EMA/PE/0000238858 PIP number EMA/PE/0000238858 Pharmaceutical form(s) All pharmaceutical forms Condition(s) / indication(s) Prevention of atherothrombotic events Route(s) of administration All routes of administration Contact for public enquiries Adamed Pharma S.A. E-mail: adamed@adamed.comTel: +48 227327700 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 16/04/2025 Compliance check done No Decision EMA/PE/0000238858 : EMA decision of 16 April 2025 on the granting of a product specific waiver for acetylsalicylic acid, rivaroxabanAdopted Reference Number: EMADOC-1700519818-2008689 English (EN) (228.65 KB - PDF)First published: 03/07/2026 View Share this page